Syndax announces $150M common stock offering

Syndax Pharmaceuticals announced that it plans to offer and sell, subject to market and other conditions, $150M of shares of its common stock in an underwritten public offering. Goldman Sachs & Co., J.P. Morgan, and Cowen are acting as joint book-running managers for the offering.